Literature DB >> 8197117

Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer.

I Sehgal1, S Powers, B Huntley, G Powis, M Pittelkow, N J Maihle.   

Abstract

After therapeutic hormone deprivation, prostate cancer cells often develop androgen-insensitive growth through mechanisms thus far undefined. Neuropeptides have been previously implicated as growth factors in some prostate cancers. Here, we demonstrate that androgen-sensitive LNCaP human prostate cancer cells produce and secrete neurotensin following androgen withdrawal. We show that while LNCaP cells express the neurotensin receptor, only androgen-deprived cells exhibit a growth response to exogenous neurotensin. We further demonstrate that androgen-stimulated cells may be refractory to exogenous neurotensin due to androgen induction of a metalloprotease active toward neurotensin. Thus, prostate cancer cells deprived of androgen develop an alternative autocrine growth mechanism involving neurotensin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8197117      PMCID: PMC43850          DOI: 10.1073/pnas.91.11.4673

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Neurotensin receptors in human meningiomas.

Authors:  S Przedborski; M Levivier; J L Cadet
Journal:  Ann Neurol       Date:  1991-11       Impact factor: 10.422

2.  Neurotensin may function as a regulatory peptide in small cell lung cancer.

Authors:  T P Davis; S Crowell; B McInturff; R Louis; T Gillespie
Journal:  Peptides       Date:  1991 Jan-Feb       Impact factor: 3.750

3.  Fluorimetric assay of the neurotensin-degrading metalloendopeptidase, endopeptidase 24.16.

Authors:  P Dauch; H Barelli; J P Vincent; F Checler
Journal:  Biochem J       Date:  1991-12-01       Impact factor: 3.857

4.  Growth factors in human prostate cancer cells: implications for an improved treatment of prostate cancer.

Authors:  C Knabbe; U Kellner; M Schmahl; K D Voigt
Journal:  J Steroid Biochem Mol Biol       Date:  1991       Impact factor: 4.292

5.  CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung.

Authors:  M A Shipp; G E Tarr; C Y Chen; S N Switzer; L B Hersh; H Stein; M E Sunday; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

6.  Expression of neurotensin in endocrine tumors.

Authors:  M Kapuscinski; A Shulkes; D Read; K J Hardy
Journal:  J Clin Endocrinol Metab       Date:  1990-01       Impact factor: 5.958

7.  Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP.

Authors:  C Y Young; B T Montgomery; P E Andrews; S D Qui; D L Bilhartz; D J Tindall
Journal:  Cancer Res       Date:  1991-07-15       Impact factor: 12.701

8.  Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation.

Authors:  N Kyprianou; H F English; J T Isaacs
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

9.  Expression of neurotensin messenger RNA in a human carcinoid tumor.

Authors:  B M Evers; J Ishizuka; C M Townsend; S Rajaraman; J C Thompson
Journal:  Ann Surg       Date:  1991-10       Impact factor: 12.969

10.  Posttranscriptional regulation of neurotensin in the gut.

Authors:  B M Evers; R D Beauchamp; J Ishizuka; C M Townsend; T Alam; J Papaconstantinou; J C Thompson
Journal:  Surgery       Date:  1991-08       Impact factor: 3.982

View more
  23 in total

1.  TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.

Authors:  Z Mounir; F Lin; V G Lin; J M Korn; Y Yu; R Valdez; O H Aina; G Buchwalter; A B Jaffe; M Korpal; P Zhu; M Brown; R D Cardiff; J L Rocnik; Y Yang; R Pagliarini
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

2.  Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase.

Authors:  L F Lee; J Guan; Y Qiu; H J Kung
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

3.  Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells.

Authors:  P D Deeble; D J Murphy; S J Parsons; M E Cox
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

4.  Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling.

Authors:  M Sumitomo; R Shen; M Walburg; J Dai; Y Geng; D Navarro; G Boileau; C N Papandreou; F G Giancotti; B Knudsen; D M Nanus
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

5.  Neurotensin receptor1 antagonist SR48692 reduces proliferation by inducing apoptosis and cell cycle arrest in melanoma cells.

Authors:  Yanli Zhang; Shunqin Zhu; Liang Yi; Yaling Liu; Hongjuan Cui
Journal:  Mol Cell Biochem       Date:  2013-12-20       Impact factor: 3.396

6.  Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma.

Authors:  Xiaoqin Yin; Mengzhe Wang; Hui Wang; Huaifu Deng; Tingting He; Yue Tan; Zehua Zhu; Zhanhong Wu; Shuo Hu; Zibo Li
Journal:  Amino Acids       Date:  2017-05-23       Impact factor: 3.520

7.  Regulation of the neurotensin NT(1) receptor in the developing rat brain following chronic treatment with the antagonist SR 48692.

Authors:  I Lépée-Lorgeoux; C Betancur; F Souazé; W Rostène; A Bérod; D Pélaprat
Journal:  J Neurosci Res       Date:  2000-05-01       Impact factor: 4.164

8.  VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal.

Authors:  Irene Gutiérrez-Cañas; Nieves Rodríguez-Henche; Oscar Bolaños; María J Carmena; Juan C Prieto; María G Juarranz
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

9.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

10.  An integral approach to the etiopathogenesis of human neurodegenerative diseases (HNDDs) and cancer. Possible therapeutic consequences within the frame of the trophic factor withdrawal syndrome (TFWS).

Authors:  Salvador Harguindey; Gorka Orive; Ramón Cacabelos; Enrique Meléndez Hevia; Ramón Díaz de Otazu; Jose Luis Arranz; Eduardo Anitua
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.